Table II.
Follow-up on plan, medication, and health economic data.
| Variable | Intervention | Control | p-value3 |
| Follow-up on plan and medication 12 weeks after discharge | (n = 148) | (n = 145) | |
| GPs’ knowledge regarding the actual medication (prescription) | |||
| Patient taking medication that the GP does not know about | 51(34%) | 70(48%) | 0.02 |
| GP reporting medication that patients do not take | 42(28%) | 57(39%) | 0.05 |
| Follow-up on the discharge plan1 | |||
| Planned clinical control was completed as recommended | 41(95%) | 21(72%) | 0.02 |
| Planned para-clinical control was completed as recommended | 38(88%) | 21(68%) | 0.09 |
| Number of drugs taken – median (interquartile range) | 7(5–10) | 6(4–8) | 0.00054 |
| Number of patients with adjusted medication since discharge2 | 84(59%) | 63(44%) | 0.01 |
| Healthcare costs per patient after 26 weeks (€) | (n = 166) | (n = 165) | Extra cost in intervention group |
| Cost of intervention at hospital | 7 | 0 | 7 |
| Cost of GP's 1st home visit5 | 102 | 0 | 102 |
| Costs of district nurses at first home visit | 35 | 0 | 35 |
| Total hospital costs | 4.414 | 5.478 | −1.064 |
| Other cost in the primary sector (public health insurance) | 856 | 667 | 190 |
| Costs of medicine | 208 | 146 | 62 |
| Total | 5.622 | 6.290 | −668 |
| (95% CI € −2.334 to +916 ) |
Notes: 1Clinical control was recommended at 45 vs. 36 patients (I vs. C), para-clinical control was recommended at 51 vs. 33 patients. 2Five intervention patients and two control patients had missing values. 3Chi-squared test. 4Wilcoxon rank-sum test on non-grouped data. 5First visit. Other GP costs from the intervention are included in costs of public health insurance.